{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028691","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.520240+00:00","generated_at":"2026-05-26T16:47:59.649630+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Solid Biosciences prices $200M public offering of common stock and pre-funded warrants","bullets":["Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.","Net proceeds estimated at $187.5M after underwriting discounts and expenses; offering expected to close Feb 19, 2025.","Investors include Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, others.","Jefferies, Leerink Partners, William Blair act as joint book-runners; H.C. Wainwright as lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028691","json":"https://secwatch.observer/filing/0001193125-25-028691.json","markdown":"https://secwatch.observer/filing/0001193125-25-028691.md","text":"https://secwatch.observer/filing/0001193125-25-028691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028691/0001193125-25-028691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028691/d908068d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:47:59.649630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}